Boardroom Alpha
Boardroom Alpha
OSTX · Additional Proxy Materials (DEFA14A) · Filed July 24, 2026

Os Therapies Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
July 24, 2026
Ticker
OSTX
Accession
0001213900-26-081417
Boardroom Alpha · Filing insights

OS Therapies' board urges FOR six directors, Incentive Plan amendment, and auditor ratification for the virtual Sept 9, 2026 meeting.

About Os Therapies Inc
Market cap
$76M
1Y TSR
−23.2%
Board grade
C-
Sector
Healthcare
CEO
Paul A Romness
Last annual meeting: Sep 9, 2026 · View full Os Therapies Inc profile →

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

 

 

SCHEDULE 14A

 

 

 

Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934
(Amendment No.    )

 

Filed by the Registrant  
Filed by a Party other than the Registrant  

 

Check the appropriate box:

 

Preliminary Proxy Statement
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
Definitive Proxy Statement
Definitive Additional Materials
Soliciting Material Pursuant to § 240.14a-12

 

OS THERAPIES INCORPORATED
(Name of Registrant as Specified in its Charter)

 

 

 

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

 

Payment of Filing Fee (Check all boxes that apply):

 

No fee required
   
Fee paid previously with preliminary materials
   
Fee computed in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

 

 

 

 

 

 

 

ONLINE VOTING To vote your proxy electronically, please go to www.vstocktransfer.com/proxy and select "Proxy Voter Login" You must reference your 12 - digit control number listed below. Vstock Transfer, LLC 18 Lafayette Place Woodmere, New York 11598 CONTROL # REQUESTING A PAPER OR ELECTRONIC COPY OF THE PROXY MATERIALS Have this notice available when you request a paper or electronic copy of the proxy materials: By telephone please call (toll free) 1 - 855 - 987 - 8625 or by email at: vote@vstocktransfer.com Please include the company name and your account number in the subject line. * SPECIMEN * 1 MAIN STREET ANYWHERE PA 99999 - 9999 OS Therapies Incorporated Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Stockholders to be held on September 9, 2026 This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. If you would like to receive a paper or e - mail copy of these documents, you must request one. There is no charge for such documents to be mailed to you. Please make your request for a copy as instructed below on or before August 26, 2026 to facilitate a timely delivery. ACCESSING YOUR PROXY MATERIALS ONLINE The following Proxy Materials are available to you to review at: ir.ostherapies.com/proxy - materials - Notice for the Annual Meeting of Stockholders; - Proxy Statement for the Annual Meeting of Stockholders (including all attachments thereto); - Annual Report on Form 10 - K for the fiscal year ended December 31, 2025; and - The Proxy Card, and any amendments to the foregoing materials that are required to be furnished to stockholders. PROXY STATEMENT OVERVIEW The Annual Meeting of Stockholders of OS Therapies Incorporated will be held virtually on September 9, 2026, at 10:00 a.m. Eastern Time at the following link: https://meeting.vstocktransfer.com/OSTHERAPIESSEP26 Proposals to be voted at the meeting are listed below along with the Board of Directors' recommendations. The Board of Directors recommends you vote FOR the following: 1. To elect six (6) directors, the names of whom are set forth in the Proxy Statement, each to serve until the Company's 2027 annual meeting of stockholders and until their respective successors are duly elected and qualified; 2. To approve the amendment and restatement of the Company’s 2023 Incentive Compensation Plan, as amended, the form of which is attached as Annex A to the Proxy Statement; 3. To vote upon the ratification of the appointment of MaloneBailey, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026; and 4. To transact such other business as may properly come before the Annual Meeting, including any motion to adjourn to a later date to permit further solicitation of proxies, if necessary, or before any adjournment thereof. The Board of Directors recommends a vote "FOR" each director nominee and "FOR" all listed Proposals. PLEASE NOTE - YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares, you must go online or request a paper copy of the Proxy Materials to receive a proxy card. * SPECIMEN * AC:ACCT9999 90.00

 

 

 

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Os Therapies Inc (OSTX)

Reference

Frequently asked questions

When did Os Therapies Inc file this DEFA14A?
Os Therapies Inc (OSTX) filed this Additional Proxy Materials (DEFA14A) with the SEC on July 24, 2026. The accession number assigned by EDGAR is 0001213900-26-081417.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
OS Therapies' board urges FOR six directors, Incentive Plan amendment, and auditor ratification for the virtual Sept 9, 2026 meeting. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Os Therapies Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Os Therapies Inc has filed under CIK 1795091, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer